AMGEN ANNOUNCES TOPLINE DATA FROM LUMAKRAS® (SOTORASIB) PHASE 3 TRIAL IN NON-SMALL CELL LUNG CANCER

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/18/2026

1. SPY
2. XENE
3. NUE
4. HUBS
5. RTB
6. ONON
7. AAPL
8. TRMD
9. ACN
10. AZN

Go back to AMGEN ANNOUNCES TOPLINE DATA FROM LUMAKRAS® (SOTORASIB) PHASE 3 TRIAL IN NON-SMALL CELL LUNG CANCER
Amgen Inc (NASDAQ: AMGN) Delayed: 385.65 +5.87 (1.55%)
Previous Close $379.78    52 Week High $176.85 
Open $378.51    52 Week Low $133.64 
Day High $386.50    P/E 58.08 
Day Low $378.51    EPS $6.64 
Volume 8,467,270